Mechanisms of medial arterial calcification in diabetes

Current Pharmaceutical Design

Volumn 20, Issue 37, 2014, Pages 5870-5883

  Chistiakov, Dimitry A ^a   Sobenin, Igor A ^b   Orekhov, Alexander N ^c,d   Bobryshev, Yuri V ^e  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^d Institute for Atherosclerosis Research   (Russian Federation)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Atherosclerosis; Diabetes; Medial arterial calcification; Mineralizing matrix vesicles; Osteogenic transdifferentiation; Vascular smooth mucle cell

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APATITE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM PHOSPHATE; HYDROXYAPATITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR RUNX2;

ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL WALL; BONE DEVELOPMENT; CELL LINEAGE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERPHOSPHATEMIA; INFLAMMATION; INSULIN RESISTANCE; MEDIAL ARTERY CALCIFICATION; MESENCHYMAL STEM CELL; MINERALIZATION; NONHUMAN; OBESITY; OSTEOBLAST; OXIDATIVE STRESS; VASCULAR SMOOTH MUSCLE; METABOLISM; PATHOLOGY; VASCULAR CALCIFICATION;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; VASCULAR CALCIFICATION;

EID: 84911496439     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140212210451     Document Type: Article

References (237)

1. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-70.
2. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978-83.
3. Barascuk N, Ganz M, Nielsen M, et al. Abdominal aortic calcification quantified by the Morphological Atherosclerotic Calcification Distribution (MACD) index is associated with features of the metabolic syndrome. BMC Cardiovasc Disord 2011; 11: 75.
4. Reaven PD, Sacks J. Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes. Diabetologia 2005; 48: 379-85.
5. Kuller LH, Matthews KA, Sutton-Tyrrell K, Edmundowicz D, Bunker CH. Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors: the healthy women study. Arterioscler Thromb Vasc Biol 1999; 19: 2189-98.
6. Ishimura E, Okuno S, Kitatani K, et al. Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients-importance of glycaemic control. Diabe-tologia 2002; 45: 1446-8.
7. Rossi A, Targher G, Zoppini G, et al. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care 2012; 35: 1781-6.
8. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 1998; 18: 535-41.
9. Shoji T, Emoto M, Shinohara K, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 2117-24.
10. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-67.
11. Li F, McDermott MM, Li D, et al. The association of lesion eccentricity with plaque morphology and components in the superficial femoral artery: a high-spatial-resolution, multi-contrast weighted CMR study. J Cardiovasc Magn Reson 2010; 12: 37.
12. Golub EE. Biomineralization and matrix vesicles in biology and pathology. Semin Immunopathol 2011; 33: 409-17.
13. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 1976; 35: 156-62.
14. Tanimura A, McGregor DH, Anderson HC. Calcification in atherosclerosis. I. Human studies. J Exp Pathol 1986; 2: 261-73.
15. Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273: 30427-34.
16. Zhou YB, Zhang J, Cai Y, et al. Insulin resistance induces medial artery calcification in fructose-fed rats. Exp Biol Med (Maywood) 2012; 237: 50-7.
17. Zhang L, Zalewski A, Liu Y, et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 2003; 108: 472-8.
18. Hayden MR, Tyagi SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropa-thy: a malignant transformation. Cardiovasc Diabetol 2004; 3: 1.
19. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210-20.
20. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor alpha promotes in vitro calcification of vascular cells via the camp pathway. Circulation 2000; 102: 2636-42.
21. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblastlike vascular cells to calcify. J Clin Invest 1994; 93: 2106-13.
22. Radcliff K, Tang TB, Lim J, et al. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 2005; 96: 398-400.
23. Alman AC, Kinney GL, Tracy RP, et al. Prospective Association Between Inflammatory Markers and Progression of Coronary Artery Calcification in Adults With and Without Type 1 Diabetes. Diabetes Care 2013; 36: 1967-73.
24. Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markersYKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol 2010; 9: 86.
25. Al-Aly Z. Arterial calcification: a tumor necrosis factor-alpha mediated vascular Wnt-opathy. Transl Res 2008; 151: 233-9.
26. Al-Aly Z, Shao JS, Lai CF, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589-96.
27. Lai CF, Shao JS, Behrmann A, Krchma K, Cheng SL, Towler DA. TNFR1-activated reactive oxidative species signals up-regulate osteogenic Msx2 programs in aortic myofibroblasts. Endocrinology 2012; 153: 3897-910.
28. Lee HL, Woo KM, Ryoo HM, Baek JH. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010; 391: 1087-92.
29. Lencel P, Delplace S, Pilet P, et al Cell-specific effects of TNF-α and IL-1 β on alkaline phosphatase: implication for syndesmorphyte formation and vascular calcification. Lab Invest 2011; 91: 1434-42.
30. Deuell KA, Callegari A, Giachelli CM, Rosenfeld ME, Scatena M. RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treatedsmooth muscle cells: dependence on IL-6 and TNF-α. J Vasc Res 2012; 49: 510-21.
31. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001; 276: 563-8.
32. Zhang Z, Jimi E, Bothwell AL. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. J Immunol 2003; 171: 3620-6.
33. Jones DP. Redefining oxidative stress. Antioxid Redox Signal 2006; 8: 1865-1879.
34. Lapolla A, Fedele D, Traldi P. Glyco-oxidation in diabetes and related diseases. Clin Chim Acta 2005; 357: 236-50.
35. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011; 46: 217-24.
36. Wright E Jr, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006; 60: 308-14.
37. Ren X, Wei Q, Shao H, Sun Z, Liu N. A rat model of diabetic artery calcification. J Endocrinol Invest 2012; 35: 497-503.
38. Wang Z, Jiang Y, Liu N, et al. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012; 221: 387-96.
39. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord 2013; 13: 13.
40. Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009; 37: 847-54.
41. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glyca-tion end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46: 572-80.
42. Suga T, Iso T, Shimizu T, et al. Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb 2011; 18: 670-83.
43. He Z, Rask-Madsen C, King GL. Managing heart disease mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies. Eur Heart J 2003; 5: B51-7.
44. Tada Y, Yano S, Yamaguchi T, et al. Advanced Glycation End Products-induced Vascular Calcification is Mediated by Oxidative Stress: Functional Roles of NAD(P)H-oxidase. Horm Metab Res 2013; 45: 267-72.
45. Hofmann Bowman MA, Gawdzik J, Bukhari U, et al. S100A12 in Vascular Smooth Muscle Accelerates Vascular Calcification in Apolipoprotein E-Null Mice by Activating an Osteogenic Gene Regulatory Program. Arterioscler Thromb Vasc Biol 2011; 31: 337-44.
46. Towler DA. Vascular calcification: It’s all the RAGE. Artherioscler Thromb Vasc Biol 2011; 31: 237-9.
47. Byon CH, Javed A, Dai Q, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008; 283: 15319-27.
48. Byon CH, Sun Y, Chen J, et al. Runx2-upregulated receptor activator of nuclear factor kB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011; 31: 1387-1396.
49. Sun Y, Byon CH, Yuan K, et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 2012; 111: 543-52.
50. Qasim A, Mehta NN, Tadesse MG, et al. Adipokines, insulin resistance, and coronary artery calcification. J Am Coll Cardiol 2008; 52: 231-6.
51. Mehta NN, Krishnamoorthy P, Martin SS, et al. Usefulness of insulin resistance estimation and the metabolic syndrome in predicting coronary atherosclerosis in type 2 diabetes mellitus. Am J Cardiol 2011; 107: 406-11.
52. Tison GH, Blaha MJ, Budoff MJ, et al. The relationship of insulin resistanc and extracoronary calcification in the multi-ethnic study of atherosclerosis. Atherosclerosis 2011; 218: 507-10.
53. Yang F, Chen ZL, Bergeron JM, Cupples RL, Friedrichs WE. Human alpha 2-HS-glycoprotein/bovine fetuin homologue in mice: identification and developmental regulation of the gene. Biochim Biophys Acta 1992; 1130: 149-56.
54. Heiss A, Eckert T, Aretz A, et al. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 2008; 283: 14815-25.
55. Westenfeld R, Schäfer C, Smeets R, et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2008; 22: 1537-46.
56. Goustin AS, Abou-Samra AB. The "thrifty" gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal 2011; 23: 980-90.
57. Goustin AS, Derar N, Abou-Samra AB. Ahsg-fetuin blocks the metabolic arm of insulin action through its interaction with the 95-kD β-subunit of the insulin receptor. Cell Signal 2013; 25: 981-8.
58. Mori K, Emoto M, Inaba M. Fetuin-A and the cardiovascular system. Adv Clin Chem 2012; 56: 175-95.
59. Ix JH, Katz R, de Boer IH, et al. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin Chem 2012; 58: 887-95.
60. Laughlin GA, Cummins KM, Wassel CL, Daniels LB, Ix JH. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol 2012; 59: 1688-96.
61. Jensen MK, Bartz TM, Mukamal KJ, et al Fetuin-A, Type 2 Diabetes, and Risk of Cardiovascular Disease in Older Adults: The Cardiovascular Health Study. Diabetes Care 2013; 36: 1222-8.
62. Lorant DP, Grujicic M, Hoebaus C, et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care 2011; 34: 156-61.
63. Westenfeld R, Schäfer C, Krüger T, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 2009; 20: 1264-74.
64. Li ZY, Wang P, Miao CY. Adipokines in inflammation, insulin resistance and cardiovascular disease. Clin Exp Pharmacol Physiol 2011; 38: 888-96.
65. Behre CJ. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest 2007; 67: 449-58.
66. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988-91.
67. Haynes WG. Role of leptin in obesity-related hypertension. Exp Physiol 2005; 90: 683-8.
68. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005; 111: 747-53.
69. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3872-8.
70. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-301.
71. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs Bl. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630-8.
72. Iwamoto I, Fujino T, Douchi T. The leptin receptor in human osteoblasts and the direct effect of leptin on bone metabolism. Gynecol Endocrinol 2004; 19: 97-104.
73. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res 2002; 17: 200-9.
74. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17: 680-7.
75. Zeadin MG, Butcher MK, Shaughnessy SG, Werstuck GH. Leptin promotes osteoblast differentiation and mineralization of primary cultures of ascular smooth muscle cells by inhibiting glycogen synthase kinase (GSK)-3β. Biochem Biophys Res Commun 2012; 425: 924-30.
76. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000; 49: 263-71.
77. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 2006; 7: 1435-41.
78. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994; 5: 339-49.
79. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975-80.
80. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-59.
81. Brown RJ, Rader DJ. Lipases as modulators of atherosclerosis in murine models. Curr Drug Targets 2007; 8: 1307-19.
82. Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007; 50: 1735-41.
83. Martin SS, Qasim AN, Mehta NN, et al. Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes 2009; 58: 1887-92.
84. Qasim AN, Martin SS, Mehta NN, et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol 2011; 150: 17-21.
85. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipopro-tein(a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006; 26: 751-72.
86. Doucet C, Huby T, Ruiz J, Chapman MJ, Thillet J. Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis 1995; 118: 135-43.
87. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apol-ipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010; 59: 1038-45.
88. Proudfoot D, Davies JD, Skepper JN, Weissberg PL, Shanahan CM. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation 2002; 106: 3044-50.
89. Bear M, Butcher M, Shaughnessy SG. Oxidized low-density lipoprotein acts synergistically with beta-glycerophosphate to induce osteoblast differentiation in primary cultures of vascular smooth muscle cells. J Cell Biochem 2008; 105: 185-93.
90. Taylor J, Butcher M, Zeadin M, Politano A, Shaughnessy S. G. Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating Osterix expression in an Msx2-dependent manner. J Cell Biochem 2011; 112: 581-8.
91. 2, and high intravascular pressure. Circulation 2005; 111: 2364-72.
92. Ulsamer A, Ortuño MJ, Ruiz S, et al. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem 2008; 283: 3816-26.
93. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006; 4: 211-21.
94. Pirillo A, Uboldi P, Ferri N, Corsini A, Kuhn H, Catapano AL. Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. Biophys Biochem Res Commun 2012; 428: 230-3.
95. Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002; 91: 570-6.
96. Taniwaki H, Ishimura E, Tabata T, et al. Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 2005; 20: 2472-8.
97. Chiu YW, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 2010; 77: 1107-14.
98. Bostom AG, Maclean AA, Maccubbin D, Tipping D, Giezek H, Hanlon WA. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients withtype 2 diabetes. J Clin Lipidol 2011; 5: 281-7.
99. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
100. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404.
101. Ix JH, De Boer IH, Peralta CA, et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-15.
102. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-64.
103. Sarkar PD, Choudhury AB. Relationship of serum osteocalcin levels with blood glucose, insulin resistance and lipid profile in central Indian men with type 2 diabetes. Arch Physiol Biochem 2012; 118: 260-4.
104. Movahed A, Larijani B, Nabipour I, et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J Bone Miner Metab 2012; 30: 683-91.
105. Chen H, Li X, Yue R, Ren X, Zhang X, Ni A. The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients. Diabetes Res Clin Pract 2013; 100: 272-276.
106. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-69.
107. Sealand R, Razavi C, Adler RA. Diabetes Mellitus and Osteoporosis. Curr Diab Rep 2013; 13: 411-8.
108. rd, Estep HL. Serum alkaline phosphatase in diabetes mellitus. J Am Coll Nutr 1986; 5: 55-9.
109. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int 2009; 85: 228-34.
110. Prosdocimo DA, Wyler SC, Romani AM, O’Neill WC, Dubyak GR. Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphatehomeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol 2010; 298: C702-13.
111. Mozar A, Haren N, Chasseraud M, et al. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol 2008; 215: 47-54.
112. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001; 31: 509-19.
113. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-7.
114. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-12.
115. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-9.
116. Mizobuchi M, Finch JL, Martin DR, Slatopolosky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
117. Son BK, Kozaki K, Iijima K, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring gas6-axl survival pathway. Circ Res 2006; 98: 1024-31.
118. Mansfield K, Pucci B, Adams CS, Shapiro IM. Induction of apop-tosis in skeletal tissues: phosphate-mediated chick chondrocyte apoptosis is calcium dependent. Calcif Tissue Int 2003; 73: 161-72.
119. Kockx MM, DeMeyer GRY, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998; 97: 2307-15.
120. Proudfoot D, Skepper J, Hegyi L, Bennett M, Shanahan C, Weiss-berg P. Apoptosis regulates human vascular calcification in vitro. Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87: 1055-62.
121. Giachelli CM, Speer M, Li X, Rajachar R, Yang H. Regulation of vascular calcification, roles of Phosphate and Osteopontin. Circ Res 2005; 96: 717-22.
122. Massy ZA, Mentaverri R, Mozar A, Brazier M, Kamel S. The pathophysiology of vascular calcification: are osteoclast-like cells the missing link? Diabetes Metab 2008; 34 (Suppl 1): S16-20.
123. Tintut Y, Alfonso Z, Saini T, et al. Multilineage potential of cells from the artery wall. Circulation 2003; 108: 2505-10.
124. Pignolo RJ, Kassem M. Circulating osteogenic cells: implications for injury, repair, and regeneration. J Bone Miner Res 2011; 26: 1685-93.
125. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
126. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003; 108: 2070-3.
127. Howson KM, Aplin AC, Gelati M, Alessandri G, Parati EA, Nicosia RF. The postnatal rat aorta contains pericyte progenitor cells that form spheroidal colonies in suspension culture. Am J Physiol Cell Physiol 2005; 289: C1396-407.
128. Fadini GP, Albiero M, Menegazzo L, Boscaro E, Agostini C, Vigili de Kreutzenberg S, et al. Procalcific phenotypic drift of circulating progenitor cells in type 2 diabetes with coronary artery disease. Exp Diabetes Res 2012; 2012: 921685.
129. Loomans CJ, van Haperen R, Duijs JM, et al. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol Med 2009; 15: 152-9.
130. Fadini GP, Tjwa M. A role for TGF-beta in transforming endothelial progenitor cells into neointimal smooth muscle cells. Atherosclerosis 2010; 211: 32-5.
131. Gössl M, Modder UI, Atkinson EJ, Lerman A, Khosla S. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol 2008; 52: 1314-25.
132. Flammer AJ, Gössl M, Li J, et al. Patients with an HbA1c in the prediabetic and diabetic range have higher numbers of circulating cells with osteogenic and endothelial progenitor cell markers. J Clin Endocrinol Metab 2012; 97: 4761-78.
133. Pirro M, Leli C, Fabbriciani G, et al. Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos Int 2010; 21: 297-306.
134. Li G, Peng H, Corsi K, Usas A, Olshanski A, Huard J. Differential effect of BMP4 on NIH/3T3 and C2C12 cells: implications for endochondral bone formation. J Bone Miner Res 2005; 20: 1611-23.
135. Boström KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res 2011; 109: 564-77.
136. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-41.
137. Sorescu GP, Sykes M, Weiss D, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem 2003; 278: 31128-35.
138. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-54.
139. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199: 271-7.
140. Shimizu T, Tanaka T, Iso T, et al. Notch signaling pathway enhances bone morphogenetic protein 2 (BMP2) responsiveness of Msx2 gene to induce osteogenic differentiation and mineralization of vascular smooth muscle cells. J Biol Chem 2011; 286: 19138-48.
141. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 2003; 278: 45969-77.
142. Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, Canfield AE. Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 2004; 110: 2226-32.
143. Medina RJ, O’Neill CL, O’Doherty TM, et al Myeloid angiogenic cells act as alternative m2 macrophages and modulate angiogenesis through interleukin-8. Mol Med 2011; 17: 1045-55.
144. Rohde E, Malischnik C, Thaler D, et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006; 24: 357-67.
145. Ninomiya K, Takahashi A, Fujioka Y, Ishikawa Y, Yokoyama M. Transforming growth factor-beta signaling enhances transdifferentiation of macrophages into smooth muscle-like cells. Hypertens Res 2006; 29: 269-76.
146. Fadini GP, Albiero M, Menegazzo L, et al. Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ Res 2011; 108: 1112-21.
147. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18: 1842-53.
148. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005; 112 (9 Suppl): I229-34.
149. Heistad DD, Marcus ML, Law EG, Armstrong ML, Ehrhardt JC, Abboud FM. Regulation of blood flow to the aortic media in dogs. J Clin Invest 1978; 62: 133-40.
150. Hu Y, Zhang Z, Torsney E, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest 2004; 113: 1258-65.
151. Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920-30.
152. Kapustin AN, Davies JD, Reynolds JL, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011; 109: e1-12.
153. Pereira L, Andrikopoulos K, Tian J, et al. Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997; 17: 218-22.
154. Bunton TE, Biery NJ, Myers L, Gayraud B, Ramirez F, Dietz HC. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001; 88: 37-43.
155. Sugitani H, Wachi H, Mecham RP, Seyama Y. Accelerated calcification represses the expression of elastic fiber components and ly-syl oxidase in cultured bovine aortic smooth muscle cells. J Athe-roscler Thromb 2002; 9: 292-8.
156. Janzen J, Vuong PN. Arterial calcifications: Morphological aspects and their pathological implications. Z Kardiol 2001; 90 (Suppl 3): 6-11.
157. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR. Elastin degradation and calcification in an abdominal aorta injury model: Role of matrix metalloproteinases. Circulation 2004; 110: 3480-7.
158. Lee JS, Basalyga DM, Simionescu A, Isenburg JC, Simionescu DT, Vyavahare NR. Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses. Am J Pathol 2006; 168: 490-8.
159. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004; 23: 552-63.
160. Wang N, Wang X, Xing C, et al. Role of TGF-beta1 in bone matrix production in vascular smooth muscle cells induced by a high-phosphate environment. Nephron Exp Nephrol 2010; 115: e60-8.
161. Lee KS, Kim HJ, Li QL, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000; 20: 8783-92.
162. Greenblatt MB, Shim JH, Zou W, et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 2010; 120: 2457-73.
163. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-71.
164. Westendorf JJ. Transcriptional co-repressors of Runx2. J Cell Bio-chem 2006; 98: 54-64.
165. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995; 15: 1512-31.
166. Chistiakov DA, Sobenin IA, Orekhov AN. Vascular extracellular matrix in atherosclerosis. Cardiol Rev 2013; 21: 270-88.
167. New SE, Aikawa E. Cardiovascular calcification: an inflammatory disease. Circ J 2011; 75: 1305-13.
168. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489-94.
169. Laird DF, Mucalo MR, Yokogawa Y. Growth of calcium hy-droxyapatite (Ca-HAp) on cholesterol and cholestanol crystals from a simulated body fluid: A possible insight into the pathological calcifications associated with atherosclerosis. J Colloid Interface Sci 2006; 295: 348-63.
170. Byers BA, García AJ. Exogenous Runx2 expression enhances in vitro osteoblastic differentiation and mineralization in primary bone marrow stromal cells. Tissue Eng 2004; 10: 1623-32.
171. Zelzer E, Glotzer DJ, Hartmann C, et al. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 2001; 106: 97-106.
172. Saremi A, Bahn G, Reaven PD; and VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2012; 35: 2390-2.
173. Budoff MJ, Yu D, Nasir K, et al. Diabetes and progression of coronary calcium under the influence of statin therapy. Am Heart J. 2005; 149: 695-700.
174. Kalia NK, Miller LG, Nasir K, Blumenthal RS, Agrawal N, Budoff MJ. Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis 2006; 185: 394-9.
175. Gilmanov D, Bevilacqua S, Mazzone A, Glauber M. Do statins slow the process of calcification of aortic tissue valves? Interact Cardiovasc Thorac Surg 2010; 11: 297-301.
176. Kozaki K. The role of statins in vascular and valvular calcification. Clin Calcium 2006; 16: 31-6.
177. rd. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 2005; 25: 592-7.
178. Nellemann B, Gormsen LC, Dollerup J, et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 2007; 30: 3122-4.
179. Mori K, Jono S, Emoto M, et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology 2010; 61: 86-91.
180. Nezami N, Safa J, Eftekhar-Sadat AT, et al. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. Clin Biochem 2010; 43: 1294-9.
181. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204: 321-9.
182. Iijima K, Ouchi Y. Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment. Clin Calcium 2010; 20: 1719-28.
183. Nguyen N, Naik V, Speer MY. Diabetes mellitus accelerates cartilaginous metaplasia and calcification in atherosclerotic vessels of LDLr mutant mice. Cardiovasc Pathol 2013; 22: 167-75.
184. Schindler TH, Cadenas J, Facta AD, et al. Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mel-litus. Eur Heart J 2009; 30: 3064-73.
185. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009; 63: 912-29.
186. Gaillard V, Casellas D, Seguin-Devaux C, et al. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 2005; 46: 372-9.
187. Li F, Cai Z, Chen F, et al. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic Res Cardiol 2012; 107: 306.
188. Woldt E, Terrand J, Mlih M, et al. The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nat Commun 2012; 3: 1077.
189. Siasos G, Tousoulis D, Kollia C, et al. Adiponectin and cardiovascular disease: mechanisms and new therapeutic approaches. Curr Med Chem 2012; 19: 1193-209.
190. Ge L, Sotiropoulos F. Direction and magnitude of blood flow shear stresses on the leaflets of aortic valves: is there a link with valve calcification? J Biomech Eng 2010; 132: 014505.
191. Jensky NE, Criqui MH, Wright MC, Wassel CL, Brody SA, Allison MA. Blood pressure and vascular calcification. Hypertension 2010; 55: 990-7.
192. Wu SY, Yu YR, Cai Y, et al. Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood) 2012; 237: 31-7.
193. Jia G, Stormont RM, Gangahar DM, Agrawal DK. Role of matrix Gla protein in angiotensin II-induced exacerbation of vascular calcification. Am J Physiol Heart Circ Physiol 2012; 303: H523-32.
194. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 2011; 13: e11.
195. Ng K, Butlin M, Avolio AP. Persistent effect of early, brief angiotensin-converting enzyme inhibition on segmental pressure dependency of aortic stiffness in spontaneously hypertensive rats. J Hypertens 2012; 30: 1782-90.
196. Sui YB, Chang JR, Chen WJ, et al Angiotensin-(1-7) inhibits vascular calcification in rats. Peptides 2013; 42C: 25-34.
197. Nicholls SJ, Tuzcu EM, Wolski K, et al. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol 2007; 49: 263-70.
198. Bruining N, de Winter S, Roelandt JR, et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Co-ron Artery Dis 2009; 20: 409-14.
199. Salas MJ, Santana O, Escolar E, Lamas GA. Medical therapy for calcific aortic stenosis. J Cardiovasc Pharmacol Ther 2012; 17: 133-8.
200. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44: 1859-66.
201. Côté N, Couture C, Pibarot P, Després JP, Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011; 41: 1172-9.
202. Nadir MA, Wei L, Elder DH, et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011; 58: 570-6.
203. Vijan SG. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. J Indian Med Assoc 2009; 107: 178-82.
204. Ouchi Y, Akishita M, de Souza AC, Nakamura T, Orimo H. Age-related loss of bone mass and aortic/aortic valve calcification-reevaluation of recommended dietary allowance of calcium in the elderly. Ann N Y Acad Sci 1993; 676: 297-307.
205. Vogt MT, San Valentin R, Forrest KY, Nevitt MC, Cauley JA. Bone mineral density and aortic calcification: the Study of Osteoporotic Fractures. J Am Geriatr Soc 1997; 45: 140-5.
206. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
207. Izutani H, Miyagawa S, Shirakura R, et al. Recipient macrophage depletion reduces the severity of graft coronary arteriosclerosis in the rat retransplantation model. Transplant Proc 1997; 29: 861-2.
208. Ayala-López W, Xia W, Varghese B, Low PS. Imaging of atherosclerosis in apoliprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med 2010; 51: 768-74.
209. Ylitalo R, Oksala O, Ylä-Herttuala S, Ylitalo P. Effects of clodro-nate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med 1994; 123: 769-76.
210. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-24.
211. Price PA, Omid N, Than TN, Williamson MK. The amino bisphos-phonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 2002; 71: 356-63.
212. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes 2012; 5: 47-54.
213. Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 2010; 5 (Suppl 1): S31-40.
214. Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysisdiabetic patients receiving calcium binders. Nephrol Dial Transplant 2006; 21: 3215-22.
215. Frazão JM, Adragão T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin Pract 2012; 120: 108-19.
216. Chen NX, Kircelli F, O’Neill KD, Chen X, Moe SM. Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney Int 2010; 77: 436-42.
217. Shimizu T, Tanaka T, Iso T, Kawai-Kowase K, Kurabayashi M. Azelnidipine inhibits Msx2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells. Int Heart J 2012; 53: 331-5.
218. Alcocer L, Bendersky M, Acosta J, Urina-Triana M. Use of calcium channel blockers in cardiovascular risk reduction: issues in Latin America. Am J Cardiovasc Drugs 2010; 10: 143-54.
219. Yamagichi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 2004; 30: 169-75.
220. Inaba S, Iwai M, Tomono Y, et al. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens 2009; 22: 145-50.
221. Yamagichi S, Matsui T, Nakamura K. Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker. Med Hypotheses 2007; 68: 1096-8.
222. Pageau SC. Denosumab. Mabs 2009; 1: 210-5.
223. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009; 175: 473-8.
224. Stewart AJ, Schmid R, Blindauer CA, Paisey SJ, Farquharson C. Comparative modelling of human PHOSPHO1 reveals a new group of phosphatases within the haloacid dehalogenase superfamily. Protein Eng 2003; 16: 889-95.
225. Houston B, Stewart AJ, Farquharson C. PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage. Bone 2004; 34: 629-37.
226. Huesa C, Yadav MC, Finnilä MA, et al. PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. Bone 2011; 48: 1066-74.
227. Kiffer-Moreira T, Yadav MC, Zhu D, et al. Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. J Bone Miner Res 2013; 28: 81-91.
228. Lomashvili KA, Garg P, Narisawa S, Millan JL, O’Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-30.
229. Narisawa S, Fröhlander N, Millán JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn 1997; 208: 432-46.
230. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164: 1199-209.
231. Delomenède M, Buchet R, Mebarek S. Lansoprazole is an uncompetitive inhibitor of tissue-nonspecific alkaline phosphatase. Acta Biochim Pol 2009; 56: 301-5.
232. Chang L, Duy do L, Mébarek S, et al. Synthesis and evaluation of thiophenyl derivatives as inhibitors of alkaline phosphatase. Bioorg Med Chem Lett 2011; 21: 2297-301.
233. Narisawa S, Harmey D, Yadav MC, O’Neill WC, Hoylaerts MF, Millán JL. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007; 22: 1700-10.
234. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010; 3: 109-21.
235. Bhambri A, Del Rosso JQ. Calciphylaxis: a review. J Clin Aesthet Dermatol 2008; 1: 38-41.
236. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 4: 4.
237. Raymonds CB, Vazny LD. Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm 2008; 65: 1419-29.